Avantor (NYSE:AVTR) Receives New Coverage from Analysts at Wells Fargo & Company

Wells Fargo & Company began coverage on shares of Avantor (NYSE:AVTRFree Report) in a report published on Tuesday morning, Benzinga reports. The brokerage issued an overweight rating and a $30.00 price objective on the stock.

Several other research analysts have also recently weighed in on AVTR. TD Cowen increased their price objective on Avantor from $28.00 to $31.00 and gave the stock a buy rating in a research report on Monday, July 29th. Royal Bank of Canada restated an outperform rating and issued a $31.00 price target on shares of Avantor in a research report on Monday, July 29th. Robert W. Baird raised their price target on Avantor from $26.00 to $27.00 and gave the stock an outperform rating in a research report on Monday, July 29th. Stifel Nicolaus raised their price target on Avantor from $27.00 to $28.00 and gave the stock a buy rating in a research report on Monday, July 29th. Finally, Evercore ISI decreased their price target on Avantor from $28.00 to $27.00 and set an outperform rating on the stock in a research report on Tuesday, July 2nd. Four research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of Moderate Buy and an average target price of $27.40.

Read Our Latest Stock Analysis on AVTR

Avantor Stock Up 0.9 %

AVTR stock opened at $25.61 on Tuesday. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.59 and a quick ratio of 1.05. The stock has a market capitalization of $17.40 billion, a price-to-earnings ratio of 65.67, a PEG ratio of 2.71 and a beta of 1.32. The business’s fifty day moving average price is $23.18 and its two-hundred day moving average price is $24.08. Avantor has a fifty-two week low of $16.63 and a fifty-two week high of $28.00.

Avantor (NYSE:AVTRGet Free Report) last posted its quarterly earnings data on Friday, July 26th. The company reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.23 by $0.02. The firm had revenue of $1.70 billion for the quarter, compared to analysts’ expectations of $1.70 billion. Avantor had a return on equity of 12.40% and a net margin of 5.28%. On average, equities analysts anticipate that Avantor will post 1.01 earnings per share for the current year.

Institutional Trading of Avantor

A number of hedge funds have recently made changes to their positions in AVTR. 1832 Asset Management L.P. lifted its stake in shares of Avantor by 1,634.9% in the second quarter. 1832 Asset Management L.P. now owns 8,530,118 shares of the company’s stock worth $180,839,000 after acquiring an additional 8,038,451 shares during the period. Norges Bank acquired a new position in shares of Avantor in the fourth quarter worth approximately $156,455,000. CCLA Investment Management lifted its stake in shares of Avantor by 147,220.3% in the first quarter. CCLA Investment Management now owns 4,720,144 shares of the company’s stock worth $120,828,000 after acquiring an additional 4,716,940 shares during the period. Point72 Asset Management L.P. acquired a new position in shares of Avantor in the fourth quarter worth approximately $93,433,000. Finally, Sound Shore Management Inc. CT acquired a new position in shares of Avantor in the second quarter worth approximately $76,412,000. 95.08% of the stock is owned by institutional investors and hedge funds.

Avantor Company Profile

(Get Free Report)

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.

Read More

Analyst Recommendations for Avantor (NYSE:AVTR)

Receive News & Ratings for Avantor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avantor and related companies with MarketBeat.com's FREE daily email newsletter.